Trial · NCT04994977
Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery
NCT04994977, Phase 1, Terminated, Weill Medical College of Cornell University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery. Trials, record NCT04994977. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04994977
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery
- NCT number
- NCT04994977
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 1 participants, actual
- Lead sponsor
- Weill Medical College of Cornell University
- Conditions
- Atypical Choroid Plexus Papilloma, Choroid Plexus Carcinoma
- Interventions
- Melphalan, Carboplatin, Topotecan
- First posted
- 2021-08-06
- Last updated
- 2026-06-08
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety of Intra-arterial Chemotherapy in Subjects With ACPP and CPC, Measured by the Number of Serious Adverse Events That Are Reported as at Least Possible Related to the Intervention That Occur in Subjects on the Trial | about 6 months since the start of therapy | |
| Secondary | The Number of Successful Angiography Procedures, Determined by Examination of Vasculature and Assessment of Catheter Placement | On Day 1 of the trial for each subject | |
| Secondary | The Number of Patients With a Tumor Volume Reduction Response, Determined by MRI Assessments | Between 4-6 weeks after intra-arterial chemotherapy | |
| Secondary | The Number of Patients With a Tumor Vascularity Reduction Response, Determined by MRI Assessments | Between 4-6 weeks after intra-arterial chemotherapy | |
| Secondary | The Success of Second Look Surgery Determined by Measuring the Extent of Tumor Resection | Around 7 weeks after intra-arterial chemotherapy, during second look surgery | The number of participants with successful second look surgery defined by gross total resection of residual tumor |
| Secondary | The Success of Second Look Surgery Determined by Amount of Blood Loss | Around 7 weeks after intra-arterial chemotherapy, during second look surgery | The number of participants with successful second look surgery determined by amount of blood loss. If the amount of blood loss is insignificant i.e. the surgery does not necessitate blood transfusion, then the surgery is deemed successful. |
| Secondary | The Success of Second Look Surgery Determined by Percent of Blood Loss | Around 7 weeks after intra-arterial chemotherapy, during second look surgery | |
| Other | Extent of Pathology Correlation to Tumor Vascularity and Tumor Viability | Around 7 weeks after intra-arterial chemotherapy | Determined by comparison of pathology reports and surgical outcomes |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04994977
GET https://conductscience.org/api/trials/v1/NCT04994977/registered